FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/Highlighting the efficacy and safety profile of modern anti-obesity drugs, focusing on liraglutide, semaglutide, and tirzepatide.
연구 도서관으로 돌아가기
liraglutidesemaglutidetirzepatide

Highlighting the efficacy and safety profile of modern anti-obesity drugs, focusing on liraglutide, semaglutide, and tirzepatide.

May 16, 2026
Share

원본 논문

Medications for Obesity: A Review.

Gudzune Kimberly A et al.JAMA2024
Emergent 연구

이 주제에 대한 잠재적인 결과가 있지만 추가 검증이 필요합니다. 이러한 발견은 유망하지만 확실하지 않습니다.

이 분석에 대해 알아보기

이 기사는 위의 원본 논문에서 발견한 결과를 피테이드 연구 커뮤니티에게 이해하기 쉬운 언어로 분해합니다. 우리의 목표는 가장 중요한 사항을 강조하는 것입니다 — 실용적 의미, 증거의 강도, 그리고 현재 진행 중인 연구에 대한 의미.

Modern Anti-Obesity Drugs: A Game-Changer in Weight Management

Published: May 16, 2026 | Source: JAMA (2024) | Category: liraglutide, semaglutide, tirzepatide

Overview

A recent review published in JAMA highlights the significant weight loss benefits of modern anti-obesity medications like liraglutide, semaglutide, and tirzepatide when used alongside lifestyle changes. This research underscores a promising new era for peptide therapy in combating obesity-related health risks.

Study Background

Obesity is a global epidemic affecting nearly 19% of women and 14% of men worldwide, contributing to increased morbidity from conditions such as type 2 diabetes, hypertension, and dyslipidemia. Prior research has shown that anti-obesity medications (AOMs) can modify biological processes related to appetite, but their efficacy and safety profiles have been inconsistent. This review aimed to synthesize data from multiple clinical trials to provide a clearer understanding of the benefits and risks associated with these drugs.

What the Research Found

The meta-analysis revealed substantial weight loss benefits for liraglutide (4.7% greater than placebo), semaglutide (11.4%), and tirzepatide (12.4%) when used in conjunction with lifestyle interventions. These medications mimic enteropancreatic hormones that regulate appetite, leading to significant improvements not only in weight but also in cardiometabolic health markers such as blood pressure, cholesterol levels, and glucose control.

Specifically:

  • Liraglutide: 6321 participants across 18 randomized clinical trials showed a 4.7% greater weight loss compared to placebo.
  • Semaglutide: 4421 participants across 5 RCTs demonstrated an 11.4% greater weight loss than placebo.
  • Tirzepatide (15 mg): 1972 participants in 6 RCTs experienced a 12.4% greater weight loss compared to placebo.

These drugs also exhibited fewer gastrointestinal adverse effects compared to orlistat, with common side effects including nausea (28%-44%), diarrhea (21%-30%), and constipation (11%-24%).

What This Means for Peptide Users

For individuals managing obesity through peptide therapy, this research suggests that incorporating liraglutide, semaglutide, or tirzepatide into their regimen could yield significant weight loss benefits. These medications offer a more targeted approach to appetite regulation and metabolic health improvement compared to traditional anti-obesity drugs.

Limitations and Caveats

While the findings are promising, several limitations must be acknowledged:

  • Methodological Variability: The study relies on data from multiple clinical trials with varying methodologies and patient populations, which may affect generalizability.
  • Long-Term Safety: Long-term safety profiles of these medications remain less understood compared to their short-term efficacy.
  • Patient Adherence: Compliance with lifestyle interventions alongside medication use can be challenging for some patients.

How This Compares to Previous Research

Previous studies have shown mixed results regarding the effectiveness and side effect profiles of anti-obesity drugs. However, this review consolidates evidence from numerous clinical trials, providing a more robust assessment of modern medications like liraglutide, semaglutide, and tirzepatide.

Our Analysis

PeptideVault's analysis indicates that while these findings are encouraging for patients seeking effective weight management solutions, caution is warranted due to the limitations noted. The data suggests a significant potential benefit from using these peptide-based medications in conjunction with lifestyle changes, but further research is needed to fully understand long-term outcomes and safety.

Key Takeaways

  • Efficacy: Modern anti-obesity drugs like liraglutide, semaglutide, and tirzepatide offer substantial weight loss benefits when used alongside lifestyle interventions.
  • Safety Profile: These medications have fewer gastrointestinal side effects compared to older drugs but may cause nausea, diarrhea, and constipation in some patients.
  • Further Research Needed: Long-term safety studies are essential for a comprehensive understanding of these treatments.

Original Source

Citation: Gudzune Kimberly A, Kushner Robert F (2024). Medications for Obesity: A Review.. JAMA. DOI: 10.1001/jama.2024.10816

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

편집자의 주석

이 분석은 Peptide Contacts 연구 팀에 의해 작성되었습니다. 항상 원문을 참조하고 자격 있는 의료 전문가와 상담하기 위해 원본 논문 전체 방법론 및 데이터는 여기에서 확인하실 수 있습니다. 원래 출판물은 {source}에서 확인하실 수 있습니다. PubMed.

관련 연구

Comments

Sign in to join the discussion

이 분석은 교차 검토된 연구를 기반으로 교육 목적용으로 생성되었습니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 피테이드 기반 치료법을 사용하기 전에 항상 자격 있는 의료 전문가와 상담하십시오.